Kibow Biotech, Inc.
Profile
https://www.dropbox.com/s/i5v3htuvgm8he6u/Kibow%20ASN2016%20Promotional%20Flyer.pdf?dl=0
As per the recently announced KidneyX program, there has been little to no innovation in the treatment of kidney disease other than Hemo or peritoneal dialysis. Now recognized as the “Gut-Kidney connection”, Kibow Biotech’s “ENTERIC DIALYSIS®” concept was originally conceived in 1997. This “enteric toxin reduction technology” is based on modulating and stabilizing the “Gut Microbiome” with a patented proprietary formulation of probiotics and prebiotics. Our flagship products Azodyl® for veterinary use and Renadyl™ for humans are patented, clinically validated formulations that promote healthy kidney function. Clinical data documents that Renadyl™ helps stabilize kidney function (GFR) by metabolizing several uremic toxins that diffuse from circulating blood into the bowel as a consequence of CKD and dysbiosis. In combination with standard of care therapy, Renadyl shows the potential to improve patient outcomes tremendously and as well help slow the progression of CKD with greatly improved quality of life. Systematic review and meta-analysis demonstrates potential beneficial effects of probiotics on inflammation, uremic toxins and GI symptoms in CKD and ESRD Patients.